Luo Xing, Liu Fang, Lu Jin, Cheng Yuqi, Xu Xiufeng, He Xiaolin, Xia Yongbing, Gao Changqing, Xie Xian, Zhao Yu, Gao Chunqiang, Ding Hua, He Yuefei, Zhang Lifen, Zhang Xi, Song Jianhui, Yang Shunying, Liu Liming, Chen Wenming, Liu Wei, Luo Chuanlin, Pu Ensheng, Lei Ming, Wang Yan, Sun Zanzong, Yang Rucheng, Zhou Yong, Zhu Xianrong, Wang Bo, He Shuhua, Gao Donghua, Li Zhongcai, Huang Liqiong, Wang Tianlan, Yang Guangya, Liu Hong, Zhao Jinkun, Wang Jicai
Department of Psychiatry, First Affiliated Hospital of Kumming Medical University, Yunnan, China.
Yunnan Mental Health Center, Yunnan, China.
BMC Psychiatry. 2024 Jun 12;24(1):439. doi: 10.1186/s12888-024-05874-1.
To analyze the economic benefits of paliperidone palmitate in the treatment of schizophrenia.
We collected 546 patients who met the diagnostic criteria for schizophrenia according to the 《International Statistical Classification of Diseases and Related Health Problems,10th》(ICD-10). We gathered general population data such as gender, age, marital status, and education level, then initiated treatment with paliperidone palmitate. Then Follow-up evaluations were conducted at 1, 3, 6, 9, and 12 months after the start of treatment to assess clinical efficacy, adverse reactions, and injection doses. We also collected information on the economic burden before and after 12 months of treatment, as well as the number of outpatient visits and hospitalizations in the past year to analyze economic benefits.
The baseline patients totaled 546, with 239 still receiving treatment with paliperidone palmitate 12 months later. After 12 months of treatment, the number of outpatient visits per year increased compared to before (4 (2,10) vs. 12 (4,12), Z=-5.949, P < 0.001), while the number of hospitalizations decreased (1 (1,3) vs. 1 (1,2), Z = 5.625, P < 0.001). The inpatient costs in the direct medical expenses of patients after 12 months of treatment decreased compared to before (5000(2000,12000) vs. 3000 (1000,8050), P < 0.05), while there was no significant change in outpatient expenses and direct non-medical expenses (transportation, accommodation, meal, and family accompanying expenses, etc.) (P > 0.05); the indirect costs of patients after 12 months of treatment (lost productivity costs for patients and families, economic costs due to destructive behavior, costs of seeking non-medical assistance) decreased compared to before (300(150,600) vs. 150(100,200), P < 0.05).
Palmatine palmitate reduces the number of hospitalizations for patients, as well as their direct and indirect economic burdens, and has good economic benefits.
分析棕榈酸帕利哌酮治疗精神分裂症的经济效益。
根据《国际疾病分类及相关健康问题统计分类，第10版》（ICD - 10）收集546例符合精神分裂症诊断标准的患者。收集患者的性别、年龄、婚姻状况和教育水平等一般人口学数据，然后开始使用棕榈酸帕利哌酮进行治疗。在治疗开始后的1、3、6、9和12个月进行随访评估，以评估临床疗效、不良反应和注射剂量。我们还收集了治疗12个月前后的经济负担信息，以及过去一年的门诊就诊次数和住院次数以分析经济效益。
基线患者共546例，12个月后仍有239例接受棕榈酸帕利哌酮治疗。治疗12个月后，每年门诊就诊次数较治疗前增加（4（2，10）对12（4,12），Z = -5.949，P < 0.001），而住院次数减少（1（1,3）对1（1,2），Z = 5.625，P < 0.001）。治疗12个月后患者直接医疗费用中的住院费用较治疗前降低（5000（2000,12000）对3000（1000,8050），P < 0.05），而门诊费用和直接非医疗费用（交通、住宿、餐饮和家属陪同费用等）无显著变化（P > 0.05）；治疗12个月后患者的间接费用（患者及家属的生产力损失成本、破坏性行为导致的经济成本、寻求非医疗援助的成本）较治疗前降低（300（150,600）对150（100,200），P < 0.05）。
棕榈酸帕利哌酮可减少患者的住院次数及其直接和间接经济负担，具有良好的经济效益。
